Monday, December 23, 2024
HomeTagsR/R MZL

R/R MZL

InnoCare Announces Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

InnoCare Pharma, a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that BTK inhibitor orelabrutinib has been granted priority review...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics